Dupilumab in Patients With Chronic Spontaneous Urticaria
JAMA Dermatology · 2026
DOI: 10.1001/jamadermatol.2025.6023 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift JAMA Dermatology, 2026. Verfasst von Thomas B Casale und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Allergy and Immunology, Department of Medicine, University of South Florida, Tampa. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Chronic Urticaria. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance Chronic spontaneous urticaria (CSU) is an inflammatory disease characterized by recurrent pruritic hives and/or angioedema. Many patients with CSU remain symptomatic despite standard-of-care, histamine 1–receptor antagonist (H1-AH) treatment. Dupilumab blocks IL-4/IL-13 signaling and is approved in multiple disease states associated with type 2 inflammation. In the phase 3 LIBERTY-CSU CUPID-A trial, dupilumab significantly reduced itch and hives severity in anti−immunoglobulin E (IgE)−naive patients with CSU uncontrolled with H1-AH. However, a replicate trial (CUPID-C) was required per US Food and Drug Administration registration requirements.
Objective
To further evaluate the efficacy and safety of dupilumab vs placebo in anti-IgE–naive patients with CSU uncontrolled by H1-AH. Design, Setting, and Participants The LIBERTY-CSU CUPID-C (2022-2024) was a randomized, placebo-controlled, double-blind, 24-week phase 3 trial using the same trial design as CUPID-A (2019-2021). CUPID-A and CUPID-C were performed in 10 countries in Asia, Europe, and North and South America with anti-IgE−naive patients aged 6 to 80 years with CSU uncontrolled with H1-AH. Data were analyzed from August to September 2024.
Interventions
Dupilumab or placebo. Main Outcomes and Measures In CUPID-C and pooled CUPID-A and -C analyses, change from baseline at week 24 in Itch Severity Score over 7 days (ISS7) or Urticaria Activity Score over 7 days (UAS7), with the other as a key secondary end point, per regional regulatory requirements.
Results
The CUPID-C analysis included 151 participants (mean [SD] age, 44.7 [16.9] years; 106 females [70.2%]), of whom 77 (51%) were taking H1-AH at a dosage higher than recommended, and 90 (59.6%) had a baseline UAS7 of 28 or greater. Significant improvements in ISS7 and UAS7 were observed with dupilumab vs placebo at week 24. Least squares mean (SE) changes were −8.64 (1.41) vs −6.10 (1.40), respectively (difference: −2.54 points [95% CI, −4.65 to −0.43]; P = .02) for ISS7 and −15.86 (2.66) vs −11.21 (2.65), respectively (difference: −4.65 points [95% CI, −8.65 to −0.65]; P = .02) for UAS7. CUPID-A and -C combined data (289 participants) demonstrated greater improvements in UAS7 and ISS7. Safety outcomes were generally consistent with the known dupilumab safety profile; 77 patients (53.5%) taking dupilumab vs 81 patients (55.9%) taking placebo reported treatment-emergent adverse events in the pooled analysis. Conclusions and Relevance The CUPID-C randomized clinical trial confirmed CUPID-A findings, and pooled data demonstrated dupilumab significantly reduced urticaria activity by reducing itch and hives severity in anti-IgE–naive patients with CSU who remained symptomatic despite the use of H1-AH. Trial Registration ClinicalTrials.gov Identifier: NCT04180488
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Allergy and Immunology, Department of Medicine, University of South Florida, Tampa.
- Division of Allergy & Clinical Immunology, Department of Medicine, Johns Hopkins University School of Medicine, Johns Hopkins Asthma and Allergy Center, Baltimore, Maryland.
- Department of Pediatrics, Division of Allergy, Clinical Immunology and Dermatology, McGill University Health Centre, Montreal, Quebec, Canada.
- Department of Dermatology, Hospital del Mar Research Institute, Universitat Pompeu Fabra, Barcelona, Spain.
- Division of Allergy and Immunology, Department of Internal Medicine, University of Cincinnati College of Medicine and Bernstein Clinical Research Center, Cincinnati, Ohio.
- Division of Cutaneous Science, Department of Dermatology, Nihon University School of Medicine, Tokyo, Japan.
Zitieren
APA
Casale, T. B., Saini, S. S., Ben-Shoshan, M., Giménez-Arnau, A. M., Bernstein, J. A., Hayama, K., Amin, N., Robinson, L. B., Bauer, D., Dakin, P., Laws, E., Radin, A., & Makhija, M. (2026). Dupilumab in Patients With Chronic Spontaneous Urticaria. JAMA Dermatology. https://doi.org/10.1001/jamadermatol.2025.6023
Vancouver
Casale TB, Saini SS, Ben-Shoshan M, Giménez-Arnau AM, Bernstein JA, Hayama K, et al. Dupilumab in Patients With Chronic Spontaneous Urticaria. JAMA Dermatology. 2026. doi:10.1001/jamadermatol.2025.6023
BibTeX
@article{Casale2026,
author = {Casale, Thomas B and Saini, Sarbjit S and Ben-Shoshan, Moshe and Giménez-Arnau, Ana M and Bernstein, Jonathan A and Hayama, Koremasa and Amin, Nikhil and Robinson, Lacey B and Bauer, Deborah and Dakin, Paula and Laws, Elizabeth and Radin, Allen and Makhija, Melanie},
title = {Dupilumab in Patients With Chronic Spontaneous Urticaria},
journal = {JAMA Dermatology},
year = {2026},
doi = {10.1001/jamadermatol.2025.6023}
}
EUVIMED